Learning From Estrogen Receptor Antagonism: Structure-Based Identification of Novel Antiandrogens Effective Against Multiple Clinically Relevant Androgen Receptor Mutants

Chemical Biology and Drug Design

Volumn 79, Issue 3, 2012, Pages 300-312

  Liu, Bing ^a   Geng, Guoyan ^a   Lin, Rongtuan ^a   Ren, Cuiyan ^a   Wu, Jian Hui ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Androgen receptor; Antiandrogen; Comparative structural analysis; Estrogen receptor; IKK ; Mutation; NF B; Prostate cancer; Switch residues

Indexed keywords

ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; ANDROGEN RECEPTOR LIGAND BINDING DOMAIN; ANTIANDROGEN; BICALUTAMIDE; COMPOUND 3; ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN; HYDROXYTAMOXIFEN; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MUTANT PROTEIN; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTIANDROGEN THERAPY; ARTICLE; CANCER THERAPY; CRYSTAL STRUCTURE; CYTOTOXICITY; DOSE RESPONSE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LEARNING; LIGAND BINDING; MASS SPECTROMETRY; MOLECULAR DYNAMICS; MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN STRUCTURE; PROTON NUCLEAR MAGNETIC RESONANCE; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIMULATION; TRANSACTIVATION;

ANDROGEN RECEPTOR ANTAGONISTS; ANILIDES; BINDING SITES; CELL LINE, TUMOR; ENZYME ACTIVATION; HUMANS; I-KAPPA B KINASE; INTERLEUKIN-6; MOLECULAR DYNAMICS SIMULATION; MUTATION; NITRILES; NUCLEOSIDES; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANDROGEN; TOSYL COMPOUNDS; TRIAZINES;

EID: 84862822261     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01290.x     Document Type: Article

References (45)

1. Culig Z., Klocker H., Bartsch G., Hobisch A. (2002) Androgen receptors in prostate cancer. Endocr Relat Cancer;9:155-170.
2. Balk S.P. (2002) Androgen receptor as a target in androgen-independent prostate cancer. Urology;60:132-138.
3. Taplin M.E., Ho S.M. (2001) The endocrinology of prostate cancer. J Clin Endocrinol Metab;86:3467-3477.
4. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., Oudard S., Theodore C., James N.D., Turesson I., Rosenthal M.A., Eisenberger M.A. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med;351:1502-1512.
5. Petrylak D.P., Tangen C.M., Hussain M.H., Lara P.N. Jr, Jones J.A., Taplin M.E., Burch P.A., Berry D., Moinpour C., Kohli M., Benson M.C., Small E.J., Raghavan D., Crawford E.D. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med;351:1513-1520.
6. Agoulnik I.U., Weigel N.L. (2006) Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem;99:362-372.
7. Attard G., Swennenhuis J.F., Olmos D., Reid A.H.M., Vickers E., A'Hern R., Levink R. et al. (2009) Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res;69:2912-2918.
8. Attard G., Reid A.H.M., Olmos D., de Bono J.S. (2009) Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res;69:4937-4940.
9. Tran C., Ouk S., Clegg N.J., Chen Y., Watson P.A., Arora V., Wongvipat J. et al. (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science;324:787-790.
10. Attard G., Cooper C.S., de Bono J.S. (2009) Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell;16:458-462.
11. Shen H.C., Balk S.P. (2009) Development of androgen receptor antagonists with promising activity in castration-resistant prostate cancer. Cancer Cell;15:461-463.
12. Taplin M.E., Rajeshkumar B., Halabi S., Werner C.P., Woda B.A., Picus J., Stadler W., Hayes D.F., Kantoff P.W., Vogelzang N.J., Small E.J. (2003) Androgen receptor mutations in androgen-in dependent prostate cancer: cancer and Leukemia Group B Study 9663. J Clin Oncol;21:2673-2678.
13. Taplin M.E. (2008) Androgen receptor: role and novel therapeutic prospects in prostate cancer. Expert Rev Anticancer Ther;8:1495-1508.
14. Miyamoto H., Rahman M.M., Chang C.S. (2004) Molecular basis for the antiandrogen withdrawal syndrome. J Cell Biochem;91:3-12.
15. Chang C.y., Walther P.J., McDonnell D.P. (2001) Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer. Cancer Res;61:8712-8717.
16. Krishnan A.V., Zhao X.Y., Swami S., Brive L., Peehl D.M., Ely K.R., Feldman D. (2002) A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. Endocrinology;143:1889-1900.
17. Steketee K., Timmerman L., Ziel-van der Made A.C., Doesburg P., Brinkmann A.O., Trapman J. (2002) Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer. Int J Cancer;100:309-317.
18. Urushibara M., Ishioka J., Hyochi N., Kihara K., Hara S., Singh P., Isaacs J.T., Kageyama Y. (2007) Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors. Prostate;67:799-807.
19. Hara T., Miyazaki J., Araki H., Yamaoka M., Kanzaki N., Kusaka M., Miyamoto M. (2003) Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res;63:149-153.
20. Yoshida T., Kinoshita H., Segawa T., Nakamura E., Inoue T., Shimizu Y., Kamoto T., Ogawa O. (2005) Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Res;65:9611-9616.
21. Zhou J.M., Geng G.Y., Wu J.H. (2010) Synthesis and in vitro characterization of ionone-based chalcones as novel antiandrogens effective against multiple clinically relevant androgen receptor mutants. Invest New Drugs;28:291-298.
22. Zhou J., Geng G., Shi Q., Sauriol F., Wu J.H. (2009) Design and synthesis of androgen receptor antagonists with bulky side chains for overcoming antiandrogen resistance. J Med Chem;52:5546-5550.
23. McGinley P.L., Koh J.T. (2007) Circumventing anti-androgen resistance by molecular design. J Am Chem Soc;129:3822-3823.
24. Zhang L., Altuwaijri S., Deng F., Chen L., Lal P., Bhanot U.K., Korets R., Wenske S., Lilja H.G., Chang C., Scher H.I., Gerald W.L. (2009) NF-+ regulates androgen receptor expression and prostate cancer growth. Am J Pathol;175:489-499.
25. Jin R.J., Lho Y., Connelly L., Wang Y., Yu X., Jean L.S., Case T.C., Ellwood-Yen K., Sawyers C.L., Bhowmick N.A., Blackwell T.S., Yull F.E., Matusik R.J. (2008) The nuclear factor-+ pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res;68:6762-6769.
26. Yemelyanov A., Gasparian A., Lindholm P., Dang L., Pierce J.W., Kisseljov F., Karseladze A., Budunova I. (2006) Effects of IKK inhibitor PS1145 on NF-+ function, proliferation, apoptosis and invasion activity in prostate carcinoma cells. Oncogene;25:387-398.
27. Jenster G. (1999) The role of the androgen receptor in the development and progression of prostate cancer. Semin Oncol;26:407-421.
28. Matias P.M., Donner P., Coelho R., Thomaz M., Peixoto C., Macedo S., Otto N., Joschko S., Scholz P., Wegg A., Basler S., Schafer M., Egner U., Carrondo M.A. (2000) Structural evidence for ligand specificity in the binding domain of the human androgen receptor - Implications for pathogenic gene mutations. J Biol Chem;275:26164-26171.
29. Sack J.S., Kish K.F., Wang C.H., Attar R.M., Kiefer S.E., An Y.M., Wu G.Y., Scheffler J.E., Salvati M.E., Krystek S.R., Weinmann R., Einspahr H.M. (2001) Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci USA;98:4904-4909.
30. Bohl C.E., Miller D.D., Chen J., Bell C.E., Dalton J.T. (2005) Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. J Biol Chem;280:37747-37754.
31. Bohl C.E., Gao W., Miller D.D., Bell C.E., Dalton J.T. (2005) Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci USA;102:6201-6206.
32. Marti-Renom M.A., Stuart A.C., Fiser A., Sanchez R., Melo F., Sali A. (2000) Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct;29:291-325.
33. Kim S., Wu J., Chen H.Y., Birzin E.T., Chan W., Yang Y.T., Colwell L., Li S., Dahllund J., DiNinno F., Rohrer S.P., Schaeffer J.M., Hammond M.L. (2004) Estrogen receptor ligands. Part 4: the SAR of the syn-dihydrobenzoxathiin SERAMs. Bioorg Med Chem Lett;14:2741-2745.
34. Pearlman D.A., Case D.A., Caldwell J.W., Ross W.S., Cheatham T.E., Debolt S., Ferguson D., Seibel G., Kollman P. (1995) Amber, a package of computer-programs for applying molecular mechanics, normal-mode analysis, molecular-dynamics and free-energy calculations to simulate the structural and energetic properties of molecules. Comput Phys Commun;91:1-41.
35. Nissink J.W., Murray C., Hartshorn M., Verdonk M.L., Cole J.C., Taylor R. (2002) A new test set for validating predictions of protein-ligand interaction. Proteins;49:457-471.
36. Cornell W.D., Cieplak P., Bayly C.I., Gould I.R., Merz K.M., Ferguson D.M., Spellmeyer D.C., Fox T., Caldwell J.W., Kollman P.A. (1996) A second generation force field for the simulation of proteins, nucleic acids, and organic molecules (vol 117, pg 5179, 1995). J Am Chem Soc;118:2309.
37. Vriend G. (1990) WHAT IF: a molecular modeling and drug design program. J Mol Graph;8:52-62.
38. Georget V., Bourguet W., Lumbroso S., Makni S., Sultan C., Nicolas J.C. (2006) Glutamic acid 709 substitutions highlight the importance of the interaction between androgen receptor helices H3 and H12 for androgen and antiandrogen actions. Mol Endocrinol;20:724-734.
39. Holterhus P.M., Sinnecker G.H., Hiort O. (2000) Phenotypic diversity and testosterone-induced normalization of mutant L712F androgen receptor function in a kindred with androgen insensitivity. J Clin Endocrinol Metab;85:3245-3250.
40. Jiang Y., Palma J.F., Agus D.B., Wang Y., Gross M.E. (2010) Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem;56:1492-1495.
41. Shen H.M., Tergaonkar V. (2009) NF-kB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis;14:348-363.
42. Setlur S.R., Royce T.E., Sboner A., Mosquera J.M., Demichelis F., Hofer M.D., Mertz K.D., Gerstein M., Rubin M.A. (2007) Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer. Cancer Res;67:10296-10303.
43. Gasparian A.V., Yao Y.J., Kowalczyk D., Lyakh L.A., Karseladze A., Slaga T.J., Budunova I.V. (2002) The role of IKK in constitutive activation of NF-+ transcription factor in prostate carcinoma cells. J Cell Sci;115:141-151.
44. Lee D.F., Hung M.C. (2008) Advances in targeting IKK and IKK-related kinases for cancer therapy. Clin Cancer Res;14:5656-5662.
45. Malinowska K., Neuwirt H., Cavarretta I.T., Bektic J., Steiner H., Dietrich H., Moser P.L., Fuchs D., Hobisch A., Culig Z. (2009) Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer;16:155-169.